Clinical trial · no report yet · Phase 3
INTerpath-001
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
- NCT05933577 ↗
- Active, not recruiting
- Merck Sharp & Dohme LLC
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 32 | |
| Podcasts | 6 | |
| YouTube | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Melanoma
- Interventions
- Intismeran autogene; Pembrolizumab; Placebo
- Arms
- Intismeran autogene + Pembrolizumab · Experimental
- Placebo + Pembrolizumab · Active comparator
- Enrollment
- 1,089 (estimated)
- Primary outcomes
- Recurrence-Free Survival (RFS)
- Sponsor
- Merck Sharp & Dohme LLC with ModernaTX, Inc.
- Start
- Jul 19, 2023
- Primary completion
- Oct 26, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT05933577 · updated Sep 24, 2025